FLT3 and acute myeloid leukemia: Another example is the combination of glutaminase inhibitor CB-839 with the tyrosine kinase inhibitor (AC220-Quizartinib), which causes major loss of viability through apoptotic cell death in FLT3-mutated AML cell lines and improves the survival in a patient-derived xenograft AML mouse model [86].